https://www.selleckchem.com/pr....oducts/qnz-evp4593.h
All intended priority populations were reached, notably those who had never tested before 35% in Phase 1 and 12% in Phase 2. Over half of follow-up survey respondents reported testing sooner. Respondents reported liking the HIVST because it did not require a visit to a clinic (84%) and preferred a HIVST to testing in a clinic (92%). CONCLUSIONS Through two phases of implementation, this innovative partnership was able to reach and offer HIVSTs to priority populations across NYC. This program supports the feasibility of distributing